Latest Blogs

Nov 21, 2019
Dr. Clarissa Mathias, chair-elect of ASCO's International Affairs Committee, speaks to the incredible impact that ASCO volunteers have on cancer care around the world.
Nov 19, 2019
Dr. Aditya Bardia and I discuss the deep and sincere bonds we form not just with our patients but with their families. How can we ensure their needs are met, especially after a patient dies?
Nov 14, 2019
If you have a passion and a calling, writes Ms. Bincy Mathew, don't let the fear of what others might think keep you from achieving your goals.
Nov 13, 2019
He was lonely and afraid after a diagnosis of prostate cancer, and I hope, wherever he is, that he is doing well.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Sep 24, 2010
I have been threatening myself with the task of sitting down and doing a more thorough review of the literature and then writing something like this for some time. Now that the blogosphere at ASCO Connection gives me a less painful alternative, (yes, all you editors, you can comment as you wish but...
Aug 25, 2010
I have no intention of devoting this blog to nothing but palliative care, but since one of my patients brought it to my attention, I can't help making sure anyone who reads here has seen a few of the articles that relate to end of life discussions.
Jul 31, 2010
A couple of events this week reminded me of what I can best describe as "our calling." The first was the good-bye party for an administrative staff member in an outreach clinic I attend. She had spent most of her career working in a busy orthopedic practice and the last 6 months working with our...
Jul 13, 2010
This is a topic that has increasingly challenged me in the last decade with so many "promising new agents" that cost a fortune but fall short of delivering the home runs we all hoped for when imatinib seemed to lead the way. In my practice, which is ~90% prostate cancer care, the latest example is...
Jun 05, 2010
Although Twitter is not my forte, trying to write some impressions in a few more words is within my abilities. I am currently sitting in the cavernous lecture hall listening to Dan VonHoff's lecture and just finished hearing Doug Blayney's Presidential Address. The challenges before us as...

Pages